Knight Therapeutics Reports Second Quarter 2022 Results
— Achieves Record Quarterly Revenues and EBITDA1 — MONTREAL, Aug. 11, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2022. All currency amounts are in thousands except for share and per share amounts. All […]
Knight to Present at the Canaccord Genuity 42nd Annual Growth Conference
MONTREAL, Aug. 04, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 11:00 am ET. A copy of the investor presentation will be available […]
Notice of Knight Therapeutics’ Second Quarter 2022 Results Conference Call
MONTREAL, Aug. 04, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2022 financial results on Thursday, August 11, 2022 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight Announces Normal Course Issuer Bid
MONTREAL, July 12, 2022 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company “), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the “TSX”) of the Company’s Notice of Intention to Make a Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB, the Company proposes to purchase, from […]
Knight Therapeutics announces relaunch of AKYNZEO® in Brazil
MONTREAL, July 04, 2022 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO® (netupitant / palonosetron) in Brazil. On May 12, 2022 Knight and Helsinn Healthcare SA (“Helsinn”) announced they have entered into […]
Knight to Present at the 2022 BIO International Convention in San Diego
MONTREAL, June 07, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Amal Khouri, Chief Business Officer, is scheduled to present at the 2022 BIO International Convention on Tuesday, June 14, 2022 at 2:45 pm Pacific Time. Knight’s Business Development team will also be participating in […]
Knight to Present at the Jefferies 2022 Healthcare Conference in New York City
MONTREAL, June 03, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) a pan-America (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2022 Healthcare Conference on Friday, June 10, 2022 at 10:00 AM ET in New York City. A copy of the presentation […]
Knight Therapeutics Assumes Commercial Activities for Exelon in Colombia
MONTREAL, June 01, 2022 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Colombian affiliate, Biotoscana Farma S.A., is in the process of assuming full commercial activities for Exelon® (rivastigmine) in Colombia upon successful transfer of the marketing authorization. On May 26, 2021, Knight completed the acquisition […]
Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America
MONTREAL, May 24, 2022 — Knight Therapeutics Inc. (TSX: GUD), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America. Fostamatinib is commercially available in the United […]
Knight Therapeutics Reports First Quarter 2022 Results
MONTREAL, May 12, 2022 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2022. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1 2022 […]
